Compugen completes enrollment in MAIA-ovarian trial of COM701, readout due Q1 2027

Compugen Ltd. reported on November 9, 2026 that it has completed enrollment in its MAIA-ovarian trial, a global, randomized, placebo-controlled adaptive platform trial evaluating COM701, a potential first-in-class anti-PVRIG antibody, as maintenance monotherapy in patients with second- and third-line relapsed platinum-sensitive ovarian cancer, and remains on track to report results by the end of the first quarter of 2027.¹ The blinded trial enrolled 62 patients randomized two to one to receive either COM701 or placebo.¹ In evaluating the trial, Compugen said it intends to consider the totality of the data, including the magnitude and durability of separation between the COM701 and placebo arms and the proportion of patients remaining progression-free at six months.¹

On the partnered program, rilvegostomig is an AstraZeneca-owned PD-1/TIGIT bispecific antibody whose TIGIT component is derived from Compugen's COM902.¹ Phase 3 high-level results from the ARTEMIDE-Biliary01 trial, assessing rilvegostomig plus investigator's choice of chemotherapy versus chemotherapy alone as adjuvant treatment in 760 participants with biliary tract cancer, are now anticipated in the second half of 2027.¹ In September 2026, AstraZeneca reported first overall survival data from the Phase 2 ARTEMIDE-01 trial in first-line, checkpoint inhibitor- and chemotherapy-naive patients with PD-L1-positive non-small cell lung cancer, with median overall survival compared favorably with historical controls.¹ Compugen is eligible for up to $195 million in additional regulatory and commercial milestones plus mid-single-digit tiered royalties under its license agreement with AstraZeneca.¹

On GS-0321 (formerly COM503), licensed to Gilead, the ongoing Phase 1 dose-escalation trial is continuing to advance.¹ Compugen has received gross payments totaling $90 million from Gilead and is eligible for up to $758 million in additional milestones plus tiered royalties ranging from single digits to low double digits.¹

On cash, Compugen had approximately $117.5 million in cash, cash equivalents, short-term bank deposits and marketable securities as of September 30, 2026, and expects its cash-related balances to fund operating plans into 2029.¹